Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/Tazobactam vs Piperacillin/Tazobactam in VAP
NCT01853982Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ceftolozane + tazobactam in ventilator-associated pneumonia (VAP), sponsored by Merck & Co.. Started Jun 2013; status: terminated.
02
Drugs
ceftolozane + tazobactam
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT01853982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01853982.